



Overview of COVID-19 Projects

Blake Simmons

BSE

May 7, 2020


- Testing Working Group (Funded)
 - Digital Microfluidics for COVID-19 RT-qPCR Assay Miniaturization
 - LBNL: Nathan Hillson, Jennifer Chiniquy
 - SNL: Jess Sustarich, Kosuke Iwai, Robert Meagher, Anup Singh
- Advanced Manufacturing Working Group (Funded)
 - Probiotic vaccine (Deepika Awasthi)
- Decontamination and Sterilization Working Group (Submitted)
 - Ionic liquids (Ning Sun)
 - Ozonolysis (Antoine Snijders)
- Biodesign of Therapeutics Working Group (Submitted)




ABPDU

- CASPR Bio: Produce and purify Cas12 enzyme to accelerate testing and deployment of diagnostic kits

- Swiftscale
 - Using innovative cell-free platform to accelerate the timelines for antibody production
 - ABPDU will generate cell-pellets for Swiftscale to optimize biocatalysis process



- City of Hope's Beckman Research Institute is using supercomputing resources at Lawrence Berkeley National Laboratory's (Berkeley Lab) National Energy Research Scientific Computing Center (NERSC) to:
 - Identify small molecules that can be used to assist in the diagnosis of COVID-19
 - Design peptide libraries to mimic virus-host interactions
 - Annotate the virulence of the Italian strain as compared to the Chinese strain of SARS-CoV-2



- Collaboration between Keasling and Cox groups focused on development of an antiviral drug capable of treating SARS-CoV-2/COVID-19
- Work is focused on nucleotide analogs that are commonly employed as antiviral small molecules that disrupt RNA polymerase-mediated viral genome replication
- Nucleotide analog therapeutics that suppress flavivirus infection also have activity against SARS-CoV-2 RNA-dependent RNA Polymerases
- Initial works indicate strong antiviral activity towards SARS-CoV-2